Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

Mise à jour : Il y a 4 ans
Référence : NCT00779922

Femme et Homme

  • | Pays :
  • France
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The purpose of this study is to determine the pharmacokinetic profile of Revlimid® in patients presenting with Multiple Myeloma and impaired renal function, the safety of Revlimid® in the enrolled patients population. and evaluate the efficacy of Revlimid®-Dexamethasone combination in patients presenting MM and impaired renal function at completion of 3 cycles of treatment.


Critère d'inclusion

  • Multiple myeloma ,Impaired Renal Function

Liens